close
close

Dr. Reuter Investor Relations – NurExone presents milestones in exosome research on a global stage, IR-WORLD.com Finanzkommunikation GmbH, Story

NurExone Biologic Inc. recently strengthened its international position with numerous appearances at major conferences in the fall of 2024. The company presented its groundbreaking developments in the field of exosome-based therapy for nervous system injuries and highlighted its progress on a global level.

Strategic presence at international conferences

NurExone Biologic (ISIN: CA67059R1091) was represented at the BioProcess International in Boston¹, the Pioneering Israeli Medicine Conference in New York², at the Precision EV Forum in Cambridge and at the World Orphan Drug Congress in Barcelona.

Dr. Noa Avni, Head of R&D at NurExone, discussed the challenges of clinical application of exosome-based therapies and presented the company's technology at the Precision EV Forum in Cambridge. NurExone also led a plenary session on GMP-compliant production of exosomes, where it presented its expertise in technology transfer and production optimization. Together with other renowned sponsors such as Beckman Coulter, the company supported this outstanding event.

NurExone also took part in the World Orphan Drug Congress in Barcelona – the largest and best-known conference for rare diseases. The company is one of the few in the world to have received Orphan Drug Designation status for acute spinal cord injuries from the FDA and is currently working on recognition of this status by the European Medicines Agency (EMA). The conference therefore provided the ideal platform to showcase NurExone's pioneering exosome-based therapies, especially given the participation of leading pharmaceutical companies such as Sanofi and Alexion (AstraZeneca Rare Disease).

Opportunities for international partnerships

These high-profile appearances demonstrate the growing interest in NurExone's scientific innovations and provide the company with valuable opportunities to build international partnerships. At the same time, NurExone is strengthening its visibility in the global pharmaceutical industry and positioning itself as a pioneer in the development of exosome-based therapies.

Voice of the CEO: Setting the course for the future

Dr. Lior Shaltiel, CEO of NurExone, emphasizes the strategic importance of the global conferences: “Our active participation in leading industry conferences allows us to further develop exosome-based therapies while addressing critical challenges in the treatment of central nervous system diseases.” These events offer us unique opportunities , to present our progress, exchange ideas with industry colleagues and explore new collaboration opportunities. We are proud to expand the potential of ExoPTEN for additional indications and share our vision with the global scientific community.”

———-

Get added to the NurExone Biologic or secondary stocks mailing list. Simply send an email to Eva Reuter: [email protected] with the note: “Distributor NurExone” or “Secondary Values”.

NurExone Biologic Inc.

ISIN: CA67059R1091

Country: Israel and Canada

Sources:

¹ https://informaconnect.com/bioprocessinternational/

² https://med-conf.scienceabroad.org.il/Home

Disclaimer/Risk Notice

Conflicts of interest: There is a comprehensive IR and PR contract with NurExone Biologic. The content of the services is, among other things, to increase the company's awareness. Dr. Reuter Investor Relations therefore acts in the interests of NurExone Biologic when creating and distributing the article. This is a promotional editorial representation. NurExone Biologic shares may be owned by employees or authors of Dr. Reuter Investor Relations – taking into account the rules of the Market Abuse Regulation (MAR).

Company risks: As with any company, there are risks regarding the implementation of the business model. There is no guarantee that the business model can be implemented according to plans. Further corporate risks of NurExone can be found in the prospectus, which can be found at.

Investment risks: Investments should only be made with funds that are freely available and are not needed to secure a living. It is not certain that it will be possible to sell shares on the stock exchange at any time. In principle, stocks are always subject to the risk of a total loss.

Disclaimer: All information published in this newsletter/article is based on careful research. The information does not constitute an offer to sell the stock(s) concerned nor a request to buy or sell securities. The information is based on sources that the publisher considers to be trustworthy.

Sources: In particular, information available on the company website is taken into account for the presentation and assessment of the company's information. As a rule, there is also direct contact with the board of directors/IR team of the respective company being analyzed or presented. The article was submitted to NurExone Biologic prior to publication in order to verify the accuracy of all information.

Forward-Looking Statements

This release contains certain forward-looking statements, including statements about the Company. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” have been used. or “potential” or the negative or other variations of these words or similar words or phrases are used to identify these forward-looking statements. These statements reflect the author's current assessments and are based on information available to the author at the time of publication of this report.

Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or errors to differ materially from those discussed or implied in the forward-looking statements. These factors should be considered carefully and the reader should not place undue reliance on the forward-looking statements. Although the forward-looking statements in this press release are based on assumptions that the author believes are reasonable, readers cannot be assured that actual results will be consistent with these forward-looking statements. Dr. Reuter Investor Relations undertakes no obligation to update or revise these statements to reflect events or circumstances, except as required by law.

Responsible & contact for questions

Dr. Reuter Investor Relations

Dr. Eva Reuter

Friedrich Ebert facility 35-37

60327 Frankfurt

+49 (0) 69 1532 5857

www.dr-reuter.eu

www.small-microcap.eu

If you have any questions, please send a message to [email protected]

Transmitted by the IRW-Press News Service of IR-WORLD.com Finanzkommunikation GmbH

The creator of the message is solely responsible for the content of the message or research. This message is not investment advice or a request to enter into specific stock market transactions.